Results 191 to 200 of about 4,166,507 (358)

Software-Enhanced Drugs™: The third platform reshaping drug development. [PDF]

Proc Natl Acad Sci U S A
Lakhan SE, Wicks P.
europepmc   +1 more source

Studies on Drug Dependence, Rept. 13; Secondary Development of Psychological Dependence on Morphine

, 1972
Tomoji Yanagita, Saburo Takahashi, Nagaoki Qinuma   +2 more
openalex   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

Navigating Drug-Drug Interactions in Clinical Drug Development: A Tutorial. [PDF]

Clin Transl Sci
Lohy Das J, Ajavon-Hartmann AT, Schmith VGD.   +2 more
europepmc   +1 more source

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

Molecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy, Samuel Hartzler, Paula A. Vargas Carranza, Shyaman Jayasundara, Madison E. Yates, Nimod D. Janson, Bozhi Liu, Annaleigh Benton, Majid Kazemian, Jason A. Hanna   +9 more
wiley   +1 more source

Genetic evidence informs the direction of therapeutic modulation in drug development. [PDF]

NPJ Drug Discov
Chen R, Duffy Á, Park JK, Stein D, Schlessinger A, Itan Y, Glicksberg BS, Tinker RJ, Jordan DM, Rocheleau G, Do R.   +10 more
europepmc   +1 more source

Emerging role of ARHGAP29 in melanoma cell phenotype switching

Molecular Oncology, EarlyView.
This study gives first insights into the role of ARHGAP29 in malignant melanoma. ARHGAP29 was revealed to be connected to tumor cell plasticity, promoting a mesenchymal‐like, invasive phenotype and driving tumor progression. Further, it modulates cell spreading by influencing RhoA/ROCK signaling and affects SMAD2 activity. Rho GTPase‐activating protein
Beatrice Charlotte Tröster, Melanie Kappelmann‐Fenzl, Anja Katrin Bosserhoff, Nicole Rachinger   +3 more
wiley   +1 more source

Optimising Monoclonal Antibody Drug Development for Inflammatory Bowel Disease. [PDF]

Clin Exp Gastroenterol
Colwill M, Honap S, Danese S, Peyrin-Biroulet L.   +3 more
europepmc   +1 more source

Development of an animal model for quantitatively evaluating effects of drugs on endometriosis

, 1985
Do Won Hahn, Robert P. Carraher, Robin G. Foldesy, J.L. McGuire   +3 more
openalex   +1 more source

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

Molecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Corinna Bang, Bjørn Naume, Johannes R. Hov, Jon Amund Kyte   +7 more
wiley   +1 more source